Could sacituzumab govitecan be the new standard in treating endocrine refractory metastatic hormone receptor-positive breast cancer?
Delve into the latest findings from the TROPiCS-02 study, a phase three trial in patients with metastatic hormone receptor-positive breast cancer, presented by Dr. Sara Tolaney at ASCO 2023.
Key Points:
- The TROPiCS-02 study is a phase three trial involving patients with metastatic hormone receptor-positive breast cancer.
- Patients were randomized to receive either sacituzumab govitecan or a treatment of the physician’s choice.
- The study showed a consistent improvement in progression-free survival from about four months to 5.5 months.
- Overall survival improved significantly, going from 11.2 months to 14.5 months.
Additional Points:
- The patient population had progressed on prior endocrine therapy and had received prior taxane.
- Patients could have received 2 to 4 prior lines of chemotherapy in the metastatic setting.
Conclusion:
- The TROPiCS-02 study suggests that sacituzumab govitecan offers a significant survival benefit for patients with endocrine refractory metastatic hormone receptor-positive breast cancer, positioning it as a new standard treatment option.
Radiation Oncology Latest Posts
- FDA Approves Inavolisib Combination for Advanced Breast Cancer
- Failure in a CAR T-Cell Trial Could Unlock Multiple Treatments for Acute Myeloid Leukemia
- Lung Cancer and AI: The Time Has Come Today
- Confessions of a Former Oncology Fellow: Advice for Attending Oncologists
Did You Know?
According to the American Cancer Society, hormone receptor-positive breast cancer is the most common type of breast cancer, accounting for about 2 out of 3 cases.